Royal Philips
PHG
24.09
-0.06
-0.25%
Royal Philips
US · PHG
#821 by market cap
Listed 1970
24.09
-0.06
-0.25%
Live - 5344 symbols - heartbeat 394s ago
· 2026-10-08 07:33
Pre-market
23.89
-0.83%
After-hours
24.10
+0.04%
Overnight
23.76
-1.37%
- Market cap
- 23.55B
- P/E (TTM)i
- 18.72
- P/Bi
- 1.84
- EPSi
- 1.04
- Div yieldi
- 4.12%
- 52W posi
- 5%
Reader sentiment
Are you bullish or bearish on PHG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.02, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -1.04% YoY
Margins
- Gross margin
- 45.18%
- Operating margin
- 8.12%
- Net margin
- 5.02%
Key ratios & quality
- Enterprise valuei
- 27.81B
- Altman Z-Scorei
- 2.02
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.12B | 17.15B | 17.31B | 17.16B | 17.83B | 18.17B | 18.02B | 17.83B |
| Gross profit | 8.55B | 7.90B | 7.82B | 7.17B | 7.19B | 7.45B | 7.77B | 8.06B |
| Selling & admin expenses | 5.13B | 4.71B | 4.68B | 4.86B | 5.29B | 5.13B | 5.07B | 4.97B |
| Research & development | 1.76B | 1.79B | 1.82B | 1.81B | 2.09B | 1.89B | 1.75B | 1.70B |
| Operating profit | 1.66B | 1.39B | 1.40B | 623.00M | -177.00M | -168.00M | 513.00M | 1.45B |
| Pretax profit | 1.50B | 1.25B | 1.21B | 509.00M | -1.73B | -526.00M | 123.00M | 1.18B |
| Tax | 193.00M | 258.00M | 212.00M | -103.00M | -113.00M | -73.00M | 963.00M | 282.00M |
| Net profit | 1.10B | 1.17B | 1.20B | 3.32B | -1.61B | -463.00M | -698.00M | 897.00M |
| Basic EPS | 1 | 1 | 1 | 3 | -2 | 0 | -1 | 1 |
| Diluted EPS | 1.06 | 1.16 | 1.19 | 3.38 | -1.69 | -0.49 | -0.75 | 0.93 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.10B | 4.34B | 4.30B | 5.10B | 3.91B | 4.36B |
| Gross profit | 1.85B | 2.01B | 1.91B | 2.29B | 1.77B | 2.15B |
| Selling & admin expenses | 1.25B | 1.24B | 1.18B | 1.31B | 1.18B | 1.21B |
| Research & development | 457.00M | 402.00M | 414.00M | 427.00M | 394.00M | 484.00M |
| Operating profit | 155.00M | 401.00M | 330.00M | 565.00M | 242.00M | 610.00M |
| Pretax profit | 104.00M | 337.00M | 275.00M | 466.00M | 190.00M | 546.00M |
| Tax | 27.00M | 95.00M | 87.00M | 74.00M | 44.00M | 160.00M |
| Net profit | 72.00M | 240.00M | 187.00M | 398.00M | 146.00M | 386.00M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.08 | 0.25 | 0.19 | 0.42 | 0.16 | 0.40 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 9.57B | 9.46B | 11.23B | 10.35B | 10.26B | 9.94B | 10.02B | 9.93B |
| Cash & ST investments | 2.12B | 1.43B | 3.23B | 2.31B | 1.18B | 1.87B | 2.40B | 2.79B |
| Inventory | 2.67B | 2.77B | 2.99B | 3.45B | 4.05B | 3.49B | 3.20B | 2.87B |
| Total assets | 26.02B | 27.02B | 27.71B | 30.96B | 30.69B | 29.41B | 28.98B | 26.94B |
| Total current liabilities | 7.94B | 6.98B | 7.73B | 7.45B | 7.93B | 8.29B | 8.14B | 7.51B |
| Short-term debt | 688.00M | 382.00M | 359.00M | 310.00M | 325.00M | 334.00M | 443.00M | 1.00B |
| Long-term debt | 3.00B | 3.77B | 4.64B | 4.77B | 6.17B | 6.10B | 6.19B | 6.05B |
| Total liabilities | 13,902,000,000.00 | 14,391,000,000.00 | 15,812,000,000.00 | 16,486,000,000.00 | 17,405,000,000.00 | 17,345,000,000.00 | 16,933,000,000.00 | 15,955,000,000.00 |
| Total equity | 12.12B | 12.63B | 11.90B | 14.48B | 13.28B | 12.06B | 12.04B | 10.99B |
| Retained earnings | 8.27B | 8.30B | 7.83B | 9.34B | 6.83B | 5.40B | 3.65B | 3.58B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 8.67B | 9.06B | 9.28B | 9.93B | 9.78B | 9.33B |
| Cash & ST investments | 1.20B | 1.82B | 1.91B | 2.79B | 2.59B | 1.79B |
| Inventory | 3.33B | 3.23B | 3.26B | 2.87B | 3.11B | 3.22B |
| Total assets | 27.17B | 26.38B | 26.34B | 26.94B | 27.27B | 26.70B |
| Total current liabilities | 6.76B | 7.20B | 7.03B | 7.51B | 7.43B | 7.42B |
| Short-term debt | 513.00M | 1.24B | 1.15B | 1.00B | 1.21B | 1.15B |
| Long-term debt | 7.06B | 7.18B | 7.24B | 6.05B | 6.89B | 6.32B |
| Total liabilities | 15,439,000,000.00 | 15,971,000,000.00 | 15,756,000,000.00 | 15,955,000,000.00 | 15,848,000,000.00 | 15,225,000,000.00 |
| Total equity | 11.73B | 10.41B | 10.58B | 10.99B | 11.42B | 11.48B |
| Retained earnings | 3.73B | 3.03B | 3.21B | 3.58B | 3.71B | 3.18B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.78B | 1.81B | 2.51B | 1.63B | -173.00M | 2.14B | 1.57B | 1.17B |
| Depreciation & amortization | 1.09B | 1.34B | 1.46B | 1.32B | 1.60B | 1.26B | 1.39B | 1.12B |
| Free cash flow | 937.00M | 862.00M | 1.62B | 866.00M | -979.00M | 1.49B | 893.00M | 504.00M |
| Dividends paid | -401.00M | -453.00M | -1.00M | -482.00M | -412.00M | -2.00M | -1.00M | -328.00M |
| Stock buybacks / issuance | -948.00M | -1.32B | -297.00M | -1.61B | -175.00M | -662.00M | -411.00M | 13.00M |
| Ending cash balance | 1.69B | 1.43B | 3.23B | 2.30B | 1.17B | 1.87B | 2.40B | 2.79B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -933.00M | 387.00M | 327.00M | 1.39B | 188.00M | 376.00M |
| Depreciation & amortization | 276.00M | 266.00M | 303.00M | 278.00M | 265.00M | 381.00M |
| Free cash flow | -1.09B | 228.00M | 169.00M | 1.20B | 25.00M | 219.00M |
| Dividends paid | -- | -295.00M | -33.00M | 0 | -- | -321.00M |
| Stock buybacks / issuance | 0 | 1.00M | 7.00M | 5.00M | 12.00M | -65.00M |
| Ending cash balance | 1.19B | 1.82B | 1.91B | 2.79B | 2.59B | 1.79B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 9.05 | 9.46 | 9.70 | 25.23 | -11.62 | -3.69 | -5.84 | 7.80 |
| ROA %i | 4.25 | 4.40 | 4.34 | 11.31 | -5.22 | -1.55 | -2.40 | 3.20 |
| ROIC %i | 7.58 | 7.63 | 7.47 | 17.98 | -6.83 | -1.24 | -2.61 | 5.52 |
| 5-year avg ROE %i | 8.76 | 9.90 | 10.73 | 13.39 | 8.36 | 5.82 | 2.76 | 2.38 |
| EBIT margin %i | 9.41 | 8.96 | 8.63 | 3.98 | -8.34 | -1.21 | 2.55 | 8.28 |
| FCF / sales %i | 5.17 | 5.23 | 9.39 | 5.05 | -- | 8.21 | 4.96 | 2.83 |
| Current ratioi | 1.21 | 1.36 | 1.45 | 1.39 | 1.29 | 1.20 | 1.23 | 1.32 |
| Quick ratioi | 0.83 | 0.92 | 1.01 | 0.89 | 0.74 | 0.74 | 0.80 | 0.90 |
| Debt / assetsi | 15.09 | 19.46 | 21.47 | 19.53 | 23.92 | 24.80 | 25.85 | 28.99 |
| LT debt / equityi | 26.79 | 38.71 | 47.09 | 39.73 | 52.96 | 57.86 | 58.70 | 62.16 |
| Interest coveragei | 8.40 | 8.05 | 8.64 | 3.93 | -6.09 | -0.72 | 1.36 | 5.02 |
| Revenue CAGR (3Y) %i | 2.54 | -0.53 | -0.89 | -1.81 | 1.30 | 1.62 | 1.65 | 0.01 |
| Net income CAGR (3Y) %i | 20.43 | -6.94 | -10.52 | 44.94 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | 27.69 | 16.92 | -2.59 | -- | -2.63 | 1.03 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 3.19 | 1.46 | 1.47 | 7.80 | 8.40 | 10.21 |
| ROA %i | 1.37 | 0.58 | 0.63 | 3.20 | 3.56 | 4.20 |
| ROIC %i | 2.85 | 1.69 | 1.66 | 5.52 | 5.83 | 6.77 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 8.04 | 6.26 | 6.33 | 8.28 | 8.86 | 10.10 |
| FCF / sales %i | 0.78 | 2.46 | 3.33 | 2.83 | 9.20 | 9.13 |
| Current ratioi | 1.28 | 1.26 | 1.32 | 1.32 | 1.32 | 1.26 |
| Quick ratioi | 0.69 | 0.72 | 0.74 | 0.90 | 0.79 | 0.73 |
| Debt / assetsi | 27.86 | 31.94 | 31.83 | 28.99 | 29.70 | 27.96 |
| LT debt / equityi | 60.32 | 69.20 | 68.58 | 62.16 | 60.49 | 55.18 |
| Interest coveragei | 4.45 | 3.55 | 3.82 | 5.02 | 5.30 | 5.81 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Diagnosis & Treatment is the largest reported line at 47.32% of revenue, across 4 reported segments.
- Connected Care follows at 27.20%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Diagnosis & Treatment47.32%
Connected Care27.20%
Personal Health20.95%
Other4.53%
Quote time 2026-10-08 07:33:09 · For reference only, not investment advice and not tailored to your situation.